ThinkEquity initiated coverage of Intensity Therapeutics (INTS) with a Buy rating and $3 price target The company has pivoted its clinical focus, creating a “high-risk, high-reward investment opportunity” centered around a near-term catalyst, the analyst tells investors in a research note. The sees a “compelling opportunity” into the Phase 2 INVINCIBLE-4 study evaluating Intensity’s lead asset, INT230-6, in neoadjuvant triple-negative breast cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS:
- Intensity Therapeutics Holds Annual Stockholders’ Meeting
- Intensity Therapeutics: INT230-6 achieved 100% complete response rate in MPNST
- Intensity Therapeutics Completes $1.9 Million Stock Offering
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
- Intensity Therapeutics 6.675M share Spot Secondary priced at 30c